From £6.99 per month
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares


Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

The Shield Therapeutics short – how’s the cash crisis going, fellas – what are your auditors saying?

By Tom Winnifrith, the Sheriff of AIM | Friday 6 May 2022

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.

When I suggested Shield Therapeutics (STX) was a nailed-down short, on the basis that it would face a cash crisis by May, my analysis was met with derision by Bulletin Board Morons. “He does not understand biotech, he does not understand Shield, he’s a failed fund manager, he is ALWAYS wrong, he works in a pizza store, he’s fleeing the UK to Greece to avoid jail”, were some of the more polite comments. It is now May, and the shares are just 17p to sell. So, what next?

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.

Filed under:

Subscribe to our newsletter

Daily digest of our latest stories.

Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was



Video: Poking Bears And Black Swans



Is Stuart Ashman lying again?



So farewell then

Time left: 21:41:34